Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma

NCT04696029 is registered in ClinicalTrials.gov with Giselle Sholler as lead sponsor.

NCT NCT04696029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04696029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
Lead sponsor
Giselle Sholler
Phase
Phase 2
Overall status
Recruiting
Start date
March 29, 2021
Completion date
March 31, 2029
Enrollment
118 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

medulloblastoma